Pharmaceutical News

RSS

New data on KAPIDEX for nighttime heartburn in adults with non-erosive GERD presented at the 2009 ACG

New data being presented at the American College of Gastroenterology (ACG) 2009 Annual Scientific Meeting in San Diego showed that treatment with KAPIDEX(TM) (dexlansoprazole) delayed release capsules over a four-week period resulted in a statistically significant greater percentage of nights without heartburn in subjects with non-erosive gastroesophageal reflux disease (GERD), compared to placebo (p<0.001).

27 Oct 2009

FDA warns four companies to stop marketing illegal opioid pain relievers

The U.S. Food and Drug Administration today warned four companies that they must stop marketing unapproved codeine sulfate tablets. These drugs are opioid analgesics, commonly called narcotics, that are widely used to treat pain.

27 Oct 2009

Shire reports results of Lialda and 5-ASA persistency analyses

Shire plc, the global specialty biopharmaceutical company, presented the results of three 5-aminosalicylic acid (5-ASA) persistency analyses at ACG 2009 Annual Scientific Meeting, evaluating persistency of Lialda® (mesalamine), Asacol® (mesalamine), Pentasa® (mesalamine) (250mg and 500mg), balsalazide [combined results from generic balsalazide disodium and Colazal® (balsalazide disodium)], and Dipentum® (olsalazine sodium) (500mg).

27 Oct 2009

Study reveals LOAD therapy can eliminate bacterium in patients with gastritis and peptic ulcers

Helicobater pylori, a bacteria implicated in peptic ulcers and gastritis, was eradicated in 95 percent patients who took a 7-day course of combination therapy with levofloxacin, omeprazole, nitazoxanide (Alinia®) and doxycycline (LOAD) compared to eradication in only 80.9 percent of patients on lansoprazole, amoxicillin and clarithromycin (LAC) for seven days.

27 Oct 2009

Pregabalin reduces abdominal pain and improves sleep in women with adhesions

Pregabalin, FDA-approved for neuropathic pain (pain caused by shingles and peripheral neuropathy), effectively reduced abdominal pain and improved sleep in women with adhesions, according to a Henry Ford study.

27 Oct 2009

Anti-Infective Drugs Advisory Committee to review aztreonam for inhalation solution

Gilead Sciences, Inc. today announced that aztreonam for inhalation solution, an investigational product for the treatment of infections due to Pseudomonas aeruginosa (P. aeruginosa) in patients with cystic fibrosis (CF), is scheduled to be reviewed by the Anti-Infective Drugs Advisory Committee of the U.S. Food and Drug Administration (FDA) on December 10, 2009.

27 Oct 2009

TNF-alpha inhibitors and interleukin inhibitors to drive psoriasis drug market

Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that the continued uptake of marketed and emerging TNF-alpha inhibitors and interleukin inhibitors will drive the psoriasis drug market to increase from $3 billion in 2008 to $5.2 billion in 2018 in the United States, France, Germany, Italy, Spain, the United Kingdom and Japan.

27 Oct 2009

Arzerra drug approved by FDA for treating chronic lymphocytic leukemia

The U.S. Food and Drug Administration today approved Arzerra (ofatumumab) for patients with chronic lymphocytic leukemia (CLL), a slowly progressing cancer of the blood and bone marrow.

27 Oct 2009

Oral contraceptives increase stroke risk but benefits still outweigh risks for most users

Nearly 100 million women worldwide use birth control pills. Pills now in use contain much lower concentrations of estrogens than older preparations. The relationship between oral contraceptives and stroke has been studied and debated for decades, and studies have yielded conflicting results.

27 Oct 2009

FDA approves Berinert for adults and adolescents with HAE

The U.S. Food and Drug Administration today approved Berinert, the first treatment for acute abdominal attacks and facial swelling associated with a rare and potentially life-threatening genetic disease called hereditary angioedema (HAE).

27 Oct 2009

Natural, aspartame-free, multi-vitamins for children

Parents want to make sure their children are getting the nutrients they need to grow and thrive but sometimes it's easier said than done. According to a recent Leger Marketing survey of Canadians parents with children between the ages of three to 12 conducted on behalf of Jamieson Laboratories, almost sixty per cent of parents say their children are picky eaters with the same percentage of parents concerned their children aren't getting the proper nutrients they need for growth and development.(1)

27 Oct 2009

Inhibikase Therapeutics to illustrate the utility of IkT-001 and IkT-041 to treat multiple infectious diseases

Inhibikase Therapeutics, a specialty pharmaceutical company based in Atlanta, Georgia, will discuss simultaneous antiviral and antibacterial activity from small molecule agents at the 2009 BIOCOM Investor Conference. Employing a host-factor targeted approach, Inhibikase will illustrate the utility of IkT-001 and IkT-041 to treat multiple infectious diseases in humans.

27 Oct 2009

New data demonstrates CREON Delayed-Release Capsules improve fat absorption in adults with EPI

Solvay Pharmaceuticals, Inc. announced that new data demonstrate that CREON®( )(pancrelipase) Delayed-Release Capsules significantly improves a key measure of fat absorption in adults with exocrine pancreatic insufficiency (EPI) due to chronic pancreatitis (CP) or pancreatic surgery.

27 Oct 2009

Dartmouth explores glucorticoid side effects on bladder-cancer patients

In her most recent study of possible triggers of cancer among northern New England residents, Dartmouth epidemiologist Margaret R. Karagas, Ph.D., and her team identified an enhanced risk to the bladders of patients taking drugs that suppress the immune system.

27 Oct 2009

Champions Biotechnology expands collaboration to accelerate oncology drug development

Champions Biotechnology, Inc. (OTC Bulletin Board: CSBR), a company with a predictive preclinical platform aimed at accelerating the development and enhancing the value of oncology drugs, has established an agreement with Ortho Biotech Oncology Research & Development, a Division of Janssen Pharmaceutica NV, for the evaluation of a novel preclinical oncology therapeutic in Champions' Biomerk Tumorgraft(TM) platform.

27 Oct 2009

Innovative approach to build a new drug to treat a number of CNS diseases

Working like an architect, Prof. Hagit Eldar-Finkelman of Tel Aviv University's Sackler School of Medicine is "building" a new drug, L803-MTS, to treat a number of central nervous system (CNS) diseases like Alzheimer's. In pre-clinical studies, it also shows promise against Parkinson's, Huntington's and diabetes.

27 Oct 2009

Swine flu 'emergency' declaration could mean expedited care

President Barack Obama declared a state of emergency as the number of swine flu cases soars and vaccine production doesn't keep up with demand.

26 Oct 2009

ImmunoCellular Therapeutics to present Phase I clinical trial data of ICT-107 vaccine in New Orleans

ImmunoCellular Therapeutics, Ltd. (OTCBB: IMUC), a clinical-stage biotechnology company that is developing immune-based therapies for the treatment of brain and other cancers, today announced that it will be presenting today, at the Annual Meeting of the Congress of Neurological Surgeons in New Orleans, Louisiana at 3:15pm central time, data from its Phase I clinical trial investigating the role that its ICT-107 vaccine may play in increasing patient survival and inhibiting tumor progression in patients with glioblastoma, the most common and most aggressive type of primary brain tumor.

26 Oct 2009

Dysport, a new wrinkle fighter, available now in the United States

The story: Dysport(TM), a new wrinkle fighter, is now available in the United States. Dysport(TM) is a Botulinum-A enzyme like Botox Cosmetic. Dysport(TM) is positioned as the new arch-nemesis and first direct competitor of Botox Cosmetic in the United States.

26 Oct 2009

Cel Sci completes its production facility for Multikine Phase III clinical trial

BioMedReports, the news portal which covers Wall Street's biomedical sector and delivers financial and investment intelligence to a community of highly informed investors, was given an exclusive tour of CEL-SCI Corporation's, new, state-of-the-art manufacturing facility near Baltimore, MD where the potentially ground breaking cancer immunotherapy treatment, Multikine, will be manufactured to support an upcoming Phase III clinical trial.

26 Oct 2009

Pharmaceutical News

New data on KAPIDEX for nighttime heartburn in adults with non-erosive GERD presented at the 2009 ACG

FDA warns four companies to stop marketing illegal opioid pain relievers

Shire reports results of Lialda and 5-ASA persistency analyses

Study reveals LOAD therapy can eliminate bacterium in patients with gastritis and peptic ulcers

Pregabalin reduces abdominal pain and improves sleep in women with adhesions

Anti-Infective Drugs Advisory Committee to review aztreonam for inhalation solution

TNF-alpha inhibitors and interleukin inhibitors to drive psoriasis drug market

Arzerra drug approved by FDA for treating chronic lymphocytic leukemia

Oral contraceptives increase stroke risk but benefits still outweigh risks for most users

FDA approves Berinert for adults and adolescents with HAE

Natural, aspartame-free, multi-vitamins for children

Inhibikase Therapeutics to illustrate the utility of IkT-001 and IkT-041 to treat multiple infectious diseases

New data demonstrates CREON Delayed-Release Capsules improve fat absorption in adults with EPI

Dartmouth explores glucorticoid side effects on bladder-cancer patients

Champions Biotechnology expands collaboration to accelerate oncology drug development

Innovative approach to build a new drug to treat a number of CNS diseases

Swine flu 'emergency' declaration could mean expedited care

ImmunoCellular Therapeutics to present Phase I clinical trial data of ICT-107 vaccine in New Orleans

Dysport, a new wrinkle fighter, available now in the United States

Cel Sci completes its production facility for Multikine Phase III clinical trial

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News